Drugs / MB-CART20.1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03893019 | Mar 2019 → Jan 2023 | cutaneous melanoma | Miltenyi Biomedicine GmbH | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03664635 | Sep 2018 → Sep 2024 | B-cell non-Hodgkin lymphoma | Miltenyi Biomedicine GmbH | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06508775 | May 2024 → Dec 2040 expected | childhood acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, melanoma | Miltenyi Biomedicine GmbH | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB-CART20.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03893019 ↗ |
| Modality | Cell therapy | “autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells” NCT03664635 ↗ |
| Route | Intravenous | “administered intravenously” NCT03664635 ↗ |